UY25374A1 - Composiciones de apomorfina útiles en el tratamiento de disfunción sexual femenina - Google Patents

Composiciones de apomorfina útiles en el tratamiento de disfunción sexual femenina

Info

Publication number
UY25374A1
UY25374A1 UY25374A UY25374A UY25374A1 UY 25374 A1 UY25374 A1 UY 25374A1 UY 25374 A UY25374 A UY 25374A UY 25374 A UY25374 A UY 25374A UY 25374 A1 UY25374 A1 UY 25374A1
Authority
UY
Uruguay
Prior art keywords
amount
sexual dysfunction
female sexual
treatment
ampomorphine
Prior art date
Application number
UY25374A
Other languages
English (en)
Inventor
El-Rashidy Bruce Ronsen Ragab
El-Rashidy Ragab
Bruce Ronsen
Original Assignee
Pentech Pharmaceuticals Inc Anillinois Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pentech Pharmaceuticals Inc Anillinois Corp filed Critical Pentech Pharmaceuticals Inc Anillinois Corp
Publication of UY25374A1 publication Critical patent/UY25374A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

Forma de dosificación sublingual para el mejoramiento de la disfunción sexual femenina, que comprende apomorfina o una sal de adición de ácido farmacéuticamente aceptable de la misma, contenida en una cantidad de 2 miligramos a 12 miligramos de ampomorfina, de modo que la cantidad útil sea suficiente para incrementar el flujo de sangre intraclitorial y el flujo sanguíneo de las paredes vaginales que se produce por estimulación de de dicha mujer, pero menos que la cantidad que provoca náuseas; la dosis puede también comprender una beta-ciclodextrina (más particularmente hidroxipropil-beta-ciclodextrina). La forma de dosificación también puede incluir manitol y ácido ascórbico. Se incluye en especial una dosificación que comprende ampomorfina o sal de adición de la misma en una cantidad suficiente para mantener la concentración del plasma entre 1 a 2 nanogramos por milímetro de plasma durante la actividad sexual.
UY25374A 1998-01-30 1999-01-29 Composiciones de apomorfina útiles en el tratamiento de disfunción sexual femenina UY25374A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/016,252 US5945117A (en) 1998-01-30 1998-01-30 Treatment of female sexual dysfunction

Publications (1)

Publication Number Publication Date
UY25374A1 true UY25374A1 (es) 1999-09-27

Family

ID=21776169

Family Applications (1)

Application Number Title Priority Date Filing Date
UY25374A UY25374A1 (es) 1998-01-30 1999-01-29 Composiciones de apomorfina útiles en el tratamiento de disfunción sexual femenina

Country Status (34)

Country Link
US (2) US5945117A (es)
EP (1) EP1056419A4 (es)
JP (1) JP2002501875A (es)
KR (1) KR20010040477A (es)
CN (1) CN1250221C (es)
AR (1) AR017976A1 (es)
AU (1) AU752928B2 (es)
BG (1) BG64667B1 (es)
BR (1) BR9908038A (es)
CA (1) CA2322289A1 (es)
CO (1) CO4970819A1 (es)
CR (1) CR5959A (es)
DZ (1) DZ2714A1 (es)
GC (1) GC0000096A (es)
GT (1) GT199900013A (es)
HK (1) HK1040901B (es)
HN (1) HN1999000015A (es)
HU (1) HUP0101268A3 (es)
IL (2) IL137569A0 (es)
JO (1) JO2085B1 (es)
MA (1) MA26600A1 (es)
MX (1) MXPA00007447A (es)
NO (1) NO319821B1 (es)
NZ (1) NZ506597A (es)
PA (1) PA8467801A1 (es)
PE (1) PE20000240A1 (es)
PL (1) PL194350B1 (es)
SK (1) SK11362000A3 (es)
TN (1) TNSN99008A1 (es)
TR (1) TR200002220T2 (es)
TW (1) TW550069B (es)
UY (1) UY25374A1 (es)
WO (1) WO1999038467A1 (es)
ZA (1) ZA99686B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395744B1 (en) * 1994-04-22 2002-05-28 Queen's University At Kingston Method and compositions for the treatment or amelioration of female sexual dysfunction
US20020165122A1 (en) * 1994-04-22 2002-11-07 Heaton Jeremy P. W. Method and compositions for the treatment or amelioration of female sexual dysfunction
US20050065161A1 (en) * 1996-02-02 2005-03-24 Nitromed, Inc. Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
US6472425B1 (en) 1997-10-31 2002-10-29 Nitromed, Inc. Methods for treating female sexual dysfunctions
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
AU2003204720B2 (en) * 1998-05-29 2006-06-29 Tap Pharmaceutical Products Inc. Methods for the normalization of sexual response and amelioration of long term genital tissue degradation
JP2002518435A (ja) * 1998-06-22 2002-06-25 クイーンズ ユニバーシティ アット キングストン 女性の性機能不全の治療または改善のための方法および組成物
US20050245494A1 (en) * 1999-07-01 2005-11-03 40 J's Llc Methods to treat one or all of the defined etiologies of female sexual dysfunction
US20040254153A1 (en) * 1999-11-08 2004-12-16 Pfizer Inc Compounds for the treatment of female sexual dysfunction
BR0005797A (pt) * 2000-03-20 2001-10-16 Abbott Lab Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados
WO2001076602A1 (en) * 2000-04-07 2001-10-18 Tap Pharmaceutical Products Inc. Apomorphine derivatives and methods for their use
US6762202B2 (en) 2000-05-09 2004-07-13 Nitromed, Inc. Infrared thermography and methods of use
US6737084B2 (en) 2000-06-27 2004-05-18 Qualilife Compositions and methods for enhancing or treating female sexual response
US7223406B2 (en) * 2000-07-21 2007-05-29 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
AU2001278981A1 (en) * 2000-07-21 2002-02-05 Tom F Lue Prevention and treatment of sexual arousal disorders
US20020065286A1 (en) * 2000-08-21 2002-05-30 Davies Michael John Treatment of wounds
AU2002235129A1 (en) 2000-11-15 2002-05-27 Tap Pharmaceutical Products Inc. Treatment of anti-depression drug-induced sexual dysfunction with apomorphine
CZ20031458A3 (cs) * 2000-11-22 2004-02-18 Abbott Laboratories Léčivo pro léčení sexuální dysfunkce savce
JP2004520389A (ja) * 2001-02-08 2004-07-08 ファルマシア・コーポレーション 性的不全の治療のための早期効果発現薬剤
CN1720054A (zh) * 2002-03-19 2006-01-11 布雷恩及比扬德生物科技公司 阿朴吗啡和其类似物的糖苷和原酸酯糖苷衍生物及其用途
US20030219696A1 (en) * 2002-05-23 2003-11-27 Moreland Gerald W. Method and apparatus for preventing backflow in dental saliva evacuators
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
GB0221711D0 (en) * 2002-09-19 2002-10-30 Ardana Bioscience Ltd Methods
CA2445212A1 (en) * 2002-10-10 2004-04-10 Queen's University At Kingston Treatment of sexual dysfunction
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
BRPI0409380A (pt) * 2003-04-14 2006-04-18 Vectura Ltd composições farmacêuticas
US7306812B2 (en) 2003-05-09 2007-12-11 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
US7276246B2 (en) * 2003-05-09 2007-10-02 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
GB0314054D0 (en) * 2003-06-17 2003-07-23 Pfizer Ltd Amide derivatives as selective serotonin re-uptake inhibitors
US20050054688A1 (en) * 2003-08-08 2005-03-10 Pfizer Inc Selective serotonin reuptake inhibitors in the treatment of disease
DE10338174A1 (de) * 2003-08-20 2005-03-24 Lts Lohmann Therapie-Systeme Ag Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit
US7291640B2 (en) * 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
GB0409744D0 (en) * 2004-04-30 2004-06-09 Pfizer Ltd Novel compounds
BRPI0510453A (pt) * 2004-04-30 2007-10-30 Warner Lambert Co composto substituìdos com morfolina para o tratamento de distúrbios do sistema nervoso central
DE602006003416D1 (de) * 2005-03-21 2008-12-11 Pfizer Ltd Substituierte triazolderivate als oxytocinantagonisten
JP2008533193A (ja) * 2005-03-21 2008-08-21 ファイザー・リミテッド オキシトシン拮抗薬としての置換トリアゾール誘導体
CN101227892B (zh) * 2005-04-08 2013-06-05 舌交付有限公司 口腔给药系统
JP2009504628A (ja) * 2005-08-10 2009-02-05 ファイザー・リミテッド オキシトシン拮抗薬としての置換トリアゾール誘導体
EP2233472B1 (en) * 2006-03-28 2014-01-15 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
US7800094B2 (en) * 2007-06-11 2010-09-21 Macronix International Co., Ltd. Resistance memory with tungsten compound and manufacturing
DK2442650T3 (en) 2009-06-12 2015-12-07 Cynapsus Therapeutics Inc sublingual apomorphine
WO2011130608A1 (en) * 2010-04-15 2011-10-20 Life Science Enhancement Corporation Methods and compositions for enhancing female sexual arousal and treating female sexual dysfunction
NZ612686A (en) 2010-12-16 2015-11-27 Cynapsus Therapeutics Inc Sublingual films
US9353067B2 (en) 2011-04-10 2016-05-31 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
EP2545905A1 (en) 2011-07-11 2013-01-16 Britannia Pharmaceuticals Limited A new therapeutical composition containing apomorphine as active ingredient
JP7211706B2 (ja) 2015-04-21 2023-01-24 サノヴィオン ファーマシュティカルズ インコーポレーテッド 口腔粘膜へのアポモルフィンの投与によるパーキンソン病の治療方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4521421A (en) * 1983-09-26 1985-06-04 Eli Lilly And Company Treatment of sexual dysfunction
EP0641202A1 (en) * 1992-05-18 1995-03-08 Smithkline Beecham Plc Use of indolone derivatives for the treatment of memory disorders, sexual dysfunction and parkinson's disease
US5565466A (en) * 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
DE69534693T2 (de) * 1994-04-22 2006-08-31 Pentech Pharmaceuticals, Inc., Wheeling Sublinguale Zusammensetzung enthaltend Apomorphine zur Diagnose der funktionellen Impotenz
US5562917A (en) * 1994-12-23 1996-10-08 Pentech Pharmaceuticals, Inc. Transdermal administration of apomorphine
US5624677A (en) * 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction

Also Published As

Publication number Publication date
BG104715A (bg) 2001-02-28
NO20003845D0 (no) 2000-07-27
CN1250221C (zh) 2006-04-12
PL194350B1 (pl) 2007-05-31
PA8467801A1 (es) 2000-09-29
HUP0101268A2 (hu) 2001-09-28
IL137569A (en) 2006-08-01
JP2002501875A (ja) 2002-01-22
NZ506597A (en) 2003-07-25
GC0000096A (en) 2005-06-29
EP1056419A1 (en) 2000-12-06
JO2085B1 (en) 2000-05-21
KR20010040477A (ko) 2001-05-15
NO20003845L (no) 2000-09-28
TW550069B (en) 2003-09-01
CN1313742A (zh) 2001-09-19
US5945117A (en) 1999-08-31
IL137569A0 (en) 2001-07-24
CO4970819A1 (es) 2000-11-07
MA26600A1 (fr) 2004-12-20
ZA99686B (en) 1999-07-28
NO319821B1 (no) 2005-09-19
HK1040901A1 (en) 2002-06-28
EP1056419A4 (en) 2007-05-02
PL342062A1 (en) 2001-05-21
CR5959A (es) 1999-07-28
GT199900013A (es) 2001-07-20
TNSN99008A1 (fr) 2005-11-10
US6193992B1 (en) 2001-02-27
BG64667B1 (bg) 2005-11-30
BR9908038A (pt) 2002-01-02
TR200002220T2 (tr) 2000-12-21
HK1040901B (zh) 2006-11-24
SK11362000A3 (sk) 2001-02-12
DZ2714A1 (fr) 2003-09-01
AU752928B2 (en) 2002-10-03
AU2564499A (en) 1999-08-16
HN1999000015A (es) 1999-08-23
CA2322289A1 (en) 1999-08-05
WO1999038467A1 (en) 1999-08-05
HUP0101268A3 (en) 2002-12-28
AR017976A1 (es) 2001-10-24
MXPA00007447A (es) 2006-01-25
PE20000240A1 (es) 2000-03-31

Similar Documents

Publication Publication Date Title
UY25374A1 (es) Composiciones de apomorfina útiles en el tratamiento de disfunción sexual femenina
AR100291A2 (es) Composición catártica
BR9302738A (pt) Composicao oral substancialmente nao irritante,com sabor aceitavel
CO5271759A1 (es) Formulacion en solucion que contiene una mezcla de disolventes
US20020022655A1 (en) Leukemic cell growth inhibiting method
EP0151989A3 (en) Means for the treatment of cardiac diseases
CO5590913A2 (es) Terapia de combinacion antivirica
MD1688G2 (ro) Benzotiofen, benzofuran şi indoltiazepinone, oxazepinone şi diazepinone, compoziţie farmaceutică, metodă de inhibare a aderării leucocitelor la celulele endoteliale pentru tratamentul proceselor inflamatorii şi metodă de tratament al mamiferelor infectate cu HIV infecţie .
AR015744A1 (es) Uso de dexmedetomidina para sedacion en terapia intensiva
RU94044456A (ru) Средство для подавления дисфункционального маточного кровотечения
KR970025615A (ko) 암 전이 억제제
ES2108240T3 (es) Derivados de tiosemicarbazona de 2-formilpiridina, su preparacion y su uso como agentes antitumor.
AR006892A1 (es) Uso de formas del acido hialuronico (ha) para el tratamiento del cancer
KR890004693A (ko) 남성형 대머리와 원치 않는 모발의 성장을 치료하는 방법
CO4960654A1 (es) Metodo para el tratamiento de enfermedades fisiologicas relacionadas con el uso o con las secuelas provocadas por el uso de la cocaina u otros estimulantes psicomotores
PE33396A1 (es) Composicion para el tratamiento del ansia de nicotina y/o los sintomas de abstinencia de fumar
AR041069A1 (es) Composicion de tolterodina liquida oral
ES2105923B1 (es) Composiciones para el tratamiento de una infeccion y una enfermedad causadas por el virus de la hepatitis b (hbv).
ES2039460T3 (es) Un procedimiento para producir una solucion inyectable de glicosido de antraciclina.
ES2067206T3 (es) Composiciones farmaceuticas conteniendo 3-amino-epsilon-caprolactamas para estimular el proceso de aprendizaje y la memoria.
CO5021217A1 (es) Composiciones estables de mitoxantrona, procedimietno para prepararlas; utilizacion de dichas composiciones y medica- mentos que incluyen dichas soluciones para el tratamiento de enfermedades cancerosas
IS6555A (is) Meðferð með aðskildum skömmtum sem hafa æðaskaðandi virkni
ES2111013T3 (es) Una composicion profilactica/terapeutica que contiene ws7622a para evitar o tratar la coagulacion intravascular diseminada, la enfermedad infecciosa cronica del tracto respiratorio o la bronquitis cronica.
MX9302832A (es) Nuevo medicamento para el tratamiento de la arritmia.
MEP1108A (en) Use of specific dose of fondaparinux sodium for the treatment of acs

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20120117